March 30, 2026
Willkie is representing Stifel, Nicolaus & Company, Incorporated, as sales agent, in connection with the SEC-registered at-the-market equity offering by Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer cell therapies to treat autoimmune diseases, of its common stock for up to an aggregate amount of $100 million.
The Willkie team is led by corporate partners Christopher Forrester and Yian Huang and supported by counsel Martin Miller and associates Dong Hee (David) Lee and Leilani Lu. Partners Eugene Chang and Daniel Werb and associate Xinrui (Alex) Li advised on IP matters. Partner Laura Jehl and associate Amelia Putnam advised on privacy matters.
